Back to search

Article

Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patients

2022-03-30

Abstract excerpt

<h4>Introduction: </h4> Real-world data on Omalizumab (OMA) and Mepolizumab (MEPO) can inform their use in severe asthma (SA). We studied patients in the Wessex AsThma CoHort of difficult asthma (WATCH) to: 1. Phenotypically compare OMA or MEPO treated patients against a SA, non-biologic group (SNB). 2. Assess clinical responses to OMA and MEPO. 3. Assess the spectrum of responses to these biologics. Methods We re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4af71478-c0f5-5fc7-9279-ec0c891ecbe1
DOI
10.22541/au.164864374.43279903/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patientsDOI 10.22541/au.164864374.43279903/v1
Select a neighboring publication to make it the new centre.